Gwen Melincoff Net Worth

The estimated Net Worth of Gwen A Melincoff is at least $558 mil dollars as of 19 November 2019. Ms. Melincoff owns over 10,000 units of Collegium Pharmaceutical Inc stock worth over $362,000 and over the last 7 years she sold COLL stock worth over $0. In addition, she makes $195,984 as Independent Director at Collegium Pharmaceutical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Melincoff COLL stock SEC Form 4 insiders trading

Gwen has made over 1 trades of the Collegium Pharmaceutical Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 10,000 units of COLL stock worth $15,400 on 19 November 2019.

The largest trade she's ever made was buying 10,000 units of Collegium Pharmaceutical Inc stock on 19 November 2019 worth over $15,400. On average, Gwen trades about 476 units every 0 days since 2017. As of 19 November 2019 she still owns at least 10,000 units of Collegium Pharmaceutical Inc stock.

You can see the complete history of Ms. Melincoff stock trades at the bottom of the page.

Gwen Melincoff biography

Gwen A. Melincoff serves as Independent Director of the Company. Ms. Melincoff has served as a member of our Board since August 2017. Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Ms. Melincoff is currently managing director at Gemini Advisors LLC, a biopharmaceutical consultancy (since 2013) and an advisor to Verge Genomics, a startup drug discovery company (since 2016) and Agent Capital (since 2017). From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc., a specialist medical products company; she also served as an advisor to Phase 1 Ventures, a startup accelerator from 2015 through 2018. From September 2004 to December 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Plc (acquired by Takeda). In addition, from 2010 to 2013, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Prior to joining Shire Plc, Ms. Melincoff held managerial and business development positions at various pharmaceutical companies, including Adolor Corporation. Ms. Melincoff currently serves on the board of Photocure ASA (PHO.OL) (2017 to present), Protalix BioTherapeutics, Inc. (NYSE: PLX) and Soleno Therapeutics (NASDAQ: SLNO) (2019 to present). Previously, she served as a board member or observer on the boards of Tobira Therapeutics (acquired by Allergan), DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc. (acquired by Allergan), Kamada Ltd. (NASDAQ: KMDA), and Enterome. Ms. Melincoff holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University. Ms. Melincoff has also attained the designation of Certified Licensing Professional (CLP™). Ms. Melincoff was named one of the “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.

What is the salary of Gwen Melincoff?

As the Independent Director of Collegium Pharmaceutical Inc, the total compensation of Gwen Melincoff at Collegium Pharmaceutical Inc is $195,984. There are 15 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of $4,032,630.

How old is Gwen Melincoff?

Gwen Melincoff is 67, she's been the Independent Director of Collegium Pharmaceutical Inc since 2017. There are 2 older and 17 younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.

What's Gwen Melincoff's mailing address?

Gwen's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.

Insiders trading at Collegium Pharmaceutical Inc

Over the last 9 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund y David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.

What does Collegium Pharmaceutical Inc do?

collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex

Complete history of Ms. Melincoff stock trades at Collegium Pharmaceutical Inc, Soleno Therapeutics Inc y Protalix BioTherapeutics

Collegium Pharmaceutical Inc executives and stock owners

Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include:

• Joseph Ciaffoni,
  President, Chief Executive Officer, Director
• Scott Dreyer,
  Executive Vice President, Chief Commercial Officer
• Richard Malamut,
  Executive Vice President and Chief Medical Officer
• Paul Brannelly,
  Chief Financial Officer, Executive Vice President
• Shirley Kuhlmann,
  Executive Vice President, General Counsel, Secretary
• Alison Fleming,
  Executive Vice President, Chief Technology Officer
• Joseph J. Ciaffoni,
  Pres, CEO & Director
• Shirley R. Kuhlmann,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Richard Malamut,
  Exec. VP & Chief Medical Officer
• Michael Heffernan,
  Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Garen Bohlin,
  Independent Director
• John Fallon,
  Independent Director
• Theodore Schroeder,
  Independent Director
• John Freund,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Michael Thomas Heffernan B.S. Pharm, R.Ph.,
  Co-Founder & Chairman
• Michael Thomas Heffernan,
  Co-Founder & Chairman
• Rita Balice-Gordon,
  Director
• Scott Sudduth,
  Head of Technical Operations
• Marlo Manning,
  Head of HR
• Scott Dreyer,
  Exec. VP & Chief Commercial Officer
• Colleen Tupper,
  Exec. VP & CFO
• Jack Maroney,
  VP of Sales
• Bart J. Dunn,
  Exec. VP of Strategy & Corp. Devel.
• Alex Dasalla,
  Head of Investor Relations
• Barry S Duke,
  See remarks
• Eran Nadav,
  Director
• David Hirsch,
  Director
• Yasunori Kaneko,
  10% owner
• Venture Partners V Lp Skyli...,
  
• Capital Partners, Llc Tamme...,
  
• Thomas B Smith,
  EVP and Chief Medical Officer
• Colleen Tupper,
  EVP & Chief Financial Officer
• Patrick J Heron,
  Director
• Capital Partners, Llc Longi...,
  
• Healthcare Vi, L.P.Fhm Vi, ...,
  
• Group Holdings (Sbs) Adviso...,
  
• Venture Partners V Lp Skyli...,
  
• Neil F. Mc Farlane,
  Director